Heather Downhour, MD
Psychiatry · Greenfield, INNPI 1841398476
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 84.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $6,801 and has fallen 94.8% since, to $354 in 2025. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $73.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$9K
- Teva Pharmaceuticals USA, Inc.$340
- Otsuka America Pharmaceutical, Inc.$265
- Indivior Inc.$229
- Sunovion Pharmaceuticals Inc.$201
- AbbVie$194
- plus $400 from 9 others
What the payments were for
- Consulting fees$4,60045%
- Travel & lodging$1,48014%
- Food & beverage$3,84838%
- Education$2913%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 68 | $8,590 |
| Teva Pharmaceuticals USA, Inc. | 12 | $340 |
| Otsuka America Pharmaceutical, Inc. | 9 | $265 |
| Indivior Inc. | 6 | $229 |
| Sunovion Pharmaceuticals Inc. | 16 | $201 |
| AbbVie | 7 | $194 |
| Supernus Pharmaceuticals, Inc. | 2 | $125 |
| Lundbeck LLC | 4 | $64 |
| Ironshore Pharmaceuticals Inc. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Johnson & Johnson | 2 | $30 |
| Neurocrine Biosciences, Inc. | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,219 in reported general payments places this provider in the 90th percentile of 514 psychiatry providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 128 | $391,995 |
| AustedoDeutetrabenazine | 25 | $214,007 |
| Abilify MaintenaAripiprazole | 42 | $120,467 |
| Invega TrinzaPaliperidone Palmitate | 11 | $101,386 |
| AristadaAripiprazole Lauroxil | 26 | $80,696 |
| RexultiBrexpiprazole | 39 | $74,827 |
| VraylarCariprazine Hcl | 46 | $66,307 |
| LybalviOlanzapine/Samidorphan Malate | 31 | $50,924 |
| TrintellixVortioxetine Hydrobromide | 84 | $44,795 |
| PerserisRisperidone | 15 | $41,596 |
| Risperdal ConstaRisperidone Microspheres | 20 | $29,401 |
| Risperidone ErRisperidone Microspheres | 18 | $26,386 |
| Paliperidone ErPaliperidone | 80 | $14,884 |
| Aripiprazole | 154 | $14,661 |
| Lurasidone Hcl | 49 | $11,592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $30 | $522,782159 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $340 | $214,00725 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $265 | $195,29481 claims |
| Alkermes, Inc.Aristada, Lybalvi | $8,590 | $131,62057 claims |
| AbbVieVraylar | $194 | $66,30746 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $42 | $51,451101 claims |
| Indivior Inc.Perseris | $229 | $41,59615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Greenfield
- Steven PaulCarmel$2.9M
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$739K
- Christopher BojrabCarmel$713K
- Joseph FanelliMunster$443K
- Eric JaggersJeffersonville$260K
- Larry LambertsonFort Wayne$208K
- Louis CadyNewburgh$135K
- Charles BeasleyIndianapolis$129K
- Muhammad MunirAnderson$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.